ArticleBrain, behavior, & immunity - health2022
Towards a multidimensional model of inflamed depression.
Article in Brain, behavior, & immunity - health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Plasma proteomic profile of inflammatory depressive symptoms.Brain, behavior, & immunity - health · 2026Article
- Higher Lipopolysaccharide Levels Are Linked to Less Anhedonia and Lower Severity of Major Depressive Disorder.Brain sciences · 2026Article
- Neuroinflammation and depression: immune-brain interface mechanisms, biomarker stratification, and therapeutic strategies.Translational psychiatry · 2026Review
- Associations of uric acid and lipids with depression, dimensions of depression and anxiety symptoms.Discover mental health · 2025Article
- Inflammatory and MRI perfusion biomarkers in predicting persistence of depression: a 6-month Longitudinal Study.Translational psychiatry · 2025Article
- Magnetic resonance imaging signatures of neuroinflammation in major depressive disorder with religious and spiritual problems.Scientific reports · 2025Article
- The 'discontinuity hypothesis' of depression in later life-clinical and research implications.Age and ageing · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) continues to impose a significant burden on individuals and society. Existing data support the important role that inflammatory responses play in its pathophysiology, with new findings continuing to be reported. In this narrative review paper, we focus on three dimensions of inflamed depression: risk factors, clinical symptoms, and neurofunctional changes. We aim to answer the following questions: What characteristics most robustly discriminate between inflamed and non-inflamed depression? How can we leverage on these discriminative characteristics to classify inflamed depressed patients? One important point that has emerged is the heterogeneous nature of the relationship between inflammation and depression. Not all inflamed patients are depressed, and not all depressed patients are inflamed. Some risk factors heighten vulnerability to inflamed depression, including childhood adversity, old age, and being female. The inflamed depression subtype has been associated with distinct clinical phenotypes, most robustly with physical symptoms such as sleep problems, changes in appetite, and fatigue. Neurofunctional changes are found in the dopaminergic reward processing pathways. A better characterization of the inflamed depression subtype by leveraging multidimensional data will help craft a more precise treatment for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.